Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Lineage Cell Therapeutics is a clinical-stage biotechnology company developing investigational, allogeneic cell therapies—not a provider of approved treatments for consumers. Its approach is to turn self-renewing pluripotent cell lines into specialized cells for potential transplantation, then evaluate distinct programs for conditions affecting the retina, spinal cord, and other tissues. The programs are at different stages, and company-reported observations do not establish that a therapy is effective or approved.
What does Lineage Cell Therapeutics do?
Lineage develops cell therapies intended to replace or support specialized human cells that are absent or dysfunctional because of disease, aging, or injury. The company describes its mission and platform on its company overview and platform page.
Its platform, which Lineage calls AlloSCOPE, starts with established, self-renewing pluripotent cell lines and uses directed differentiation protocols to produce cell types with characteristics associated with particular developmental lineages. Pluripotent cells can give rise to many cell types; directed differentiation is the process of guiding them toward a more specialized identity. In principle, this gives a developer a renewable starting material for making cells intended for transplantation. The company’s description of that approach is not evidence that a specific therapy works in patients.
How does an off-the-shelf cell therapy work?
“Allogeneic” means the cells come from a donor and are intended for a recipient other than that donor. “Off-the-shelf” describes the development model: cells are produced from established cell lines for potential use across recipients, rather than being made individually from each patient’s own cells. In Lineage’s proposed model, a cell line is differentiated into a target cell type, prepared as a candidate therapy, and delivered to a tissue where the cells may replace or support cells affected by disease or injury.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →#1 Best Overall
That description explains the intended approach, not a currently available treatment. Lineage’s programs remain investigational. Whether transplanted cells survive, integrate, or improve a clinically meaningful outcome must be established through clinical testing and regulatory review; the platform rationale alone cannot answer those questions.
What is Lineage Cell Therapeutics’ pipeline?
The programs differ in target cell, condition, development stage, partners, and what their studies measure. The following comparison reflects descriptions on Lineage’s program pages and its March 2026 filing; stages and priorities can change.
| Program | Target cell and intended use | Stage and study focus | Partner or context |
|---|---|---|---|
| OpRegen / RG6501 | Retinal pigment epithelial (RPE) cells for geographic atrophy secondary to age-related macular degeneration | Phase 2a development; GAlette evaluates subretinal delivery, safety, and activity | Worldwide collaboration with Roche and Genentech |
| OPC1 | Oligodendrocyte progenitor cells for spinal cord injury | DOSED evaluates the safety and utility of a delivery device; earlier trials have long-term follow-up | Device-focused study; the study is not, by itself, evidence of restored function |
| ReSonance (ANP1) | Auditory neuron progenitor cells for sensorineural hearing loss | Preclinical | Research collaboration with William Demant Invest |
| COR1 | Corneal endothelial cells; expected indications include Fuchs endothelial corneal dystrophy and bullous keratopathy | Development stage not stated in the cited other-programs page | See Lineage’s other programs page |
| PNC1, RND1, and ILT1 | Further research initiatives | Specific target and stage not stated in the cited March 2026 filing | Listed in Lineage’s March 2026 Form 8-K |
What is OpRegen?
OpRegen, also identified as RG6501, is Lineage’s allogeneic RPE cell replacement candidate for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a form of dry AMD. Lineage describes it as being in Phase 2a development under a worldwide collaboration with Roche and Genentech. The OpRegen program page describes GAlette as evaluating subretinal surgical delivery, safety, and activity. Its stated primary objectives include delivery to target retinal regions and procedure-related adverse events; structural imaging is among the secondary assessments.
Lineage reported that, in Phase 1/2a Cohort 4, participants with less advanced GA had a mean best-corrected visual acuity change of +6.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letters among 10 treated eyes completing three-year follow-up. It separately reported a mean change of +9.0 ETDRS letters among five participants with extensive treatment coverage. These are company-reported observations from small groups, not proof of efficacy or a result that can be generalized to all patients. Lineage also describes retinal structural observations from imaging; those too are company-described study findings.
Rank #3
What is OPC1?
OPC1 is an allogeneic oligodendrocyte progenitor cell therapy candidate for spinal cord injury. Lineage’s rationale is that these cells may replace or support cells in the injured spinal cord. The OPC1 program page describes DOSED as a study of the safety and utility of a novel device for delivering OPC1 to the injury area in people with subacute and chronic spinal cord injury. A study focused on delivery-device safety and utility should not be interpreted as demonstrating that the therapy restores function.
Lineage reports earlier clinical experience comprising a five-person Phase 1 safety trial in acute thoracic injury and a 25-person Phase 1/2a trial in subacute cervical injury, with long-term follow-up. These trial histories are company-reported; their existence does not establish a confirmed treatment benefit.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How should readers interpret the pipeline?
A useful comparison starts with what each program is trying to do and what its studies actually assess—not with a ranking of which candidate is most likely to succeed.
- Target cell and intended role: OpRegen targets RPE cells in the retina; OPC1 targets oligodendrocyte progenitor cells in the spinal cord; ReSonance is aimed at auditory neuron progenitor cells.
- Condition: The named programs address GA secondary to AMD, spinal cord injury, and sensorineural hearing loss, respectively.
- Stage: Lineage describes OpRegen as Phase 2a and ReSonance as preclinical. OPC1 has earlier clinical trial histories and a delivery-device study; those are different forms of evidence and should not be collapsed into a single claim of therapeutic efficacy.
- Study measures: OpRegen’s GAlette objectives include surgical delivery and procedure-related safety, alongside activity assessments. OPC1’s DOSED study evaluates a delivery device. Read the specified endpoints before treating a study’s progress as evidence of a clinical outcome.
- Collaboration: Lineage identifies Roche and Genentech as collaborators on OpRegen and William Demant Invest as a research collaborator for ReSonance.
Program stage and focus are time-sensitive. For the latest status, consult Lineage’s program pages and filings rather than assuming that a stage or study description remains unchanged.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
